top of page

01 February 2024

UroMaster Adventure Embarks Its Journey......

Screenshot 2024-10-22 164303.png

As the curtains fall on Arab Health 2024, we are excited to embark on a ground-breaking journey with UroMaster, our latest innovation in prostate cancer diagnostics. UroMaster is not just a product; it's a paradigm shift in precision and reliability for prostate biopsy procedures.

Our journey begins with UroMaster traveling across the diverse landscapes of the Asia Pacific and the Middle East. These regions, known for their dynamic healthcare landscapes, are about to witness a revolution in prostate cancer diagnostics. UroMaster, with its state-of-the-art robotic guided fusion technology, is designed to deliver unparalleled accuracy in prostate biopsies, enhancing early detection and significantly improving patient outcomes.

Why UroMaster?

Prostate cancer is a global health concern, and early detection is key. Traditional biopsy methods come with limitations in accuracy and comfort. UroMaster addresses these challenges head-on, providing a less invasive, more accurate, and patient-friendly approach. Its advanced imaging and precision-targeting capabilities mean better diagnostics, leading to more effective treatment planning.

Our commitment goes beyond innovation; it's about impacting lives. We believe UroMaster will be a game-changer in the fight against prostate cancer, especially in regions where access to advanced healthcare technology is emerging. By introducing UroMaster in the Asia Pacific and Middle East, we are taking a step towards making high-end medical technology more accessible and improving the standard of care in these communities.

 

Stay tuned as we share updates, success stories, and insights from our journey with UroMaster! Join us in this exciting phase of growth and innovation. Together, we can make a significant impact in the world of healthcare and patient care.

Contact Us

Blk 71 Ayer Rajah Crescent #04-18/19

Singapore 139951

Phone: +65 8919 9394

Email: marketing@uromedtech.com

  • LinkedIn

Please fill in the form if you would like to get in touch with us!

1. Siddiqui MM, Rais-Bahrami S, Truong H, Stamatakis L, Vourganti S, Nix J, et al. Magnetic Resonance Imaging/Ultrasound–Fusion Biopsy Significantly Upgrades Prostate Cancer Versus Systematic 12-core Transrectal Ultrasound Biopsy. European Urology. 2013 Nov;64(5):713–9.

2. Srinivas Vourganti, Rastinehad AR, Nitin Yerram, Nix JW, Dmitry Volkin, Hoang A, et al. Multiparametric Magnetic Resonance Imaging and Ultrasound Fusion Biopsy Detect Prostate Cancer in Patients with Prior Negative Transrectal Ultrasound Biopsies. 2012 Dec 1;188(6):2152–7.

3. Power J, Ryan J, Hutchinson B, Brady D, Hannan M, Kieran O'Malley, et al. Change from transrectal to transperineal ultrasound-guided prostate biopsy under local anaesthetic eliminates sepsis as a complication. The Journal of hospital infection/Journal of hospital infection. 2022 Jul 1;125:44–7.

 

 

Copyright© UroMedTech Pte. Ltd. All rights reserved. UroMedtech Reserves the right to modify the design, specifications and features shown herein, without prior notice or obligation.

bottom of page